Why the study?
COVID-19 vaccine-associated cardiac adverse events have emerged alongside well-identified infection-related cardiac complications, prompting a comparison of their pathophysiology, diagnosis, and treatment.
This review provides a comparative overview of the pathophysiology, diagnosis, and treatment of myocarditis and pericarditis following SARS-CoV-2 infection versus COVID-19 vaccination.
Etiology-aware evaluation of myocarditis is needed now; leaves open comparative outcomes and whether management should differ by trigger.
Cardiac complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been well-identified since the beginning of the current coronavirus disease 2019 (COVID-19) pandemic. Such conditions can occur of various etiologies, such as respiratory failure and hypoxemia, direct cardiac tissue damage due to viral replication, indirect myocarditis as systemic inflammation, and the interaction of different medications. Recently, with the start of the COVID-19 vaccination programs, COVID-19 vaccine-associated cardiac adverse events (AEs) have emerged and are increasingly being reported. Although these AEs are usually mild and self-limited, they can sometimes cause severe, catastrophic outcomes. This review compares the pathophysiology, diagnosis, and treatment of the de novo SARS-CoV-2 infection-related and COVID-19 vaccine-related myocarditis and pericarditis.
No takes yet. Share an insight, caveat, or question.
Afshar et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: